Ligand Pharmaceuticals (LGND) Short-term Investments (2010 - 2026)

Ligand Pharmaceuticals' Short-term Investments history runs 17 years deep, the most recent figure standing at $664.3 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 312.85% year-over-year to $664.3 million; the TTM figure through Mar 2026 stood at $664.3 million (up 312.85% YoY), while the FY2025 annual figure was $15.6 million, down 91.5% from the prior year.
• Short-term Investments came in at $664.3 million for Q1 2026 at Ligand Pharmaceuticals, up from $15.6 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $664.3 million in Q1 2026 to a low of $11.1 million in Q3 2024.
• A 5-year average of $207.4 million and a median of $177.4 million in 2025 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments slumped 93.5% in 2024 and soared 4617.02% in 2025, its largest moves.
• Ligand Pharmaceuticals' Short-term Investments stood at $166.9 million in 2022, then retreated by 11.69% to $147.4 million in 2023, then gained by 24.77% to $183.9 million in 2024, then tumbled by 91.5% to $15.6 million in 2025, then surged by 4149.8% to $664.3 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $664.3 million, $15.6 million, and $525.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison